Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global precision medicine market size reached a value of USD 81.31 billion in 2023. The market is anticipated to grow at a CAGR of 12.3% during the forecast period of 2024-2032, reaching a value of USD 230.96 billion by 2032. The growth can be attributed to the increased demand for precision medicine, advancements in sequencing technologies, and the growing application of precision medicine in various fields.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Precision medicine is defined as a developing approach to illness treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. This method will help doctors and researchers to forecast which disease treatment and preventative efforts will work more accurately in specific groups of people. It contrasts with a one-size-fits-all approach, in which disease treatment and prevention measures are developed for the person with consideration for individual differences.
Precision medicine is relatively a new concept in the healthcare system, which includes pharmacogenomics. Pharmacogenomics is the study of how a person's response to specific medications is influenced by their genes. This relatively new area combines the study of genes and their roles with pharmacology, the science of pharmaceuticals, to create effective, secure medications and doses that are customised to genetic variations in an individual.
Scientists and doctors worldwide have accommodated huge amount of patient’s data to study and create personas for future references. This approach is used to develop targeted medicines for the patient by following the data that contains patient’s health history. This data is thoroughly studied and examined by scientists and healthcare professionals to collect the data that is useful in development of precision medicines. The research that is based on the patient’s health history is performed on the molecular data to identify changes or mutation at genetic level. It is widely used in cancer research and diseases that are genetically inherited by the patient. This data is used by next-generation sequencing (NGS) to develop the treatment and diagnose the conditions.
Numerous aspects of health and healthcare could be improved with the help of precision medicine. As the All of Us Research Program progresses and new tools and methods for handling data are developed, some of these advantages will soon become obvious. Long-term precision medicine research will produce further benefits, some of which may take years to happen.
A few of the benefits of precision medicine market include:
Some challenges for precision medicine market include the following:
The market can be categorized into the following segmentations:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Technology
Precision Medicine Market Breakup by Application
Precision Medicine Market Breakup by Therapeutic Areas
Market Breakup by End User
Precision Medicine Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The idea of precision medicine is a methodical approach meant to defeat diseases like cancer. The primary focus of many precision medicine programs is cancer. Precision oncology focuses on matching each cancer patient with the most precise and correct treatment based on their genetic profile, which may ultimately allow them to benefit from the treatment provided.
Globally rising cancer incidence, pharmacogenomics' reduction of trial-and-error drug prescribing, rising use of predictive biomarkers for cancer diagnostics, and swift technology breakthroughs in oncology are all factors driving the growth of precision medicine market.
Due to the enhanced healthcare system and significant investment in research and development, precision medicine is expected to expand in the United States. For some cancer types, such as colorectal cancer and breast cancer, precision medicine has significantly improved cancer treatment. Applications for precision medicine, which are expected to make up the majority of the market, are mostly focused on enhancing the treatment of cancerous diseases.
One of the main factors contributing to the segment's dominance is the increased incidence of cancer and the increase of drug targets for the condition that is now undergoing clinical trials. It is anticipated that the market for precision medicine would grow as a result of the government's strong financial backing and the quickening development of genetic analysis.
Oncology sector has been a pioneer in precision medicine. The widespread cytotoxicity and severe side effects of current "one size fits all" cancer medicines, together with the discovery of associated tumour-specific vulnerabilities as prospective drug targets, are probable contributing factors to the shift toward tailored therapies.
One of the first clinical success stories for targeted chemotherapy was imatinib, which targets the BCR-ABL fusion gene in chronic myelogenous leukaemia (CML) and gain-of-function mutations in the genes encoding mast/stem cell growth factor receptor KIT or platelet-derived growth factor receptor (PDGFR) in gastrointestinal stromal tumours (GISTs).
An aggressive form of breast cancer with a poor prognosis that overexpresses tyrosine-protein kinase erbB-2 (HER2) reacts favourably to trastuzumab, a monoclonal antibody that targets HER2, and has demonstrated a considerable survival benefit in these patients.
The pathway-based approach to treating cancer has come under criticism as anti-cancer medication resistance has emerged. The next generation of kinase inhibitors has been created as a result of improvements in our understanding of tumour resistance and the mutations that cause it. The T790M mutation, which confers resistance to existing EGFR inhibitors, is the target of osimertinib, a third-generation EGFR tyrosine kinase inhibitor.
Due to the KRAS gene mutation, over 40% of patients with metastatic colon cancer do not react to cetuximab and panitumumab. Due to this finding, it was suggested that the following medications only be administered to patients who did not have a KRAS gene mutation.
Diabetes Mellitus: Most patients do not achieve proper blood glucose control despite the availability of several classes of DM medications, both oral and insulin preparations because treatment is frequently based on trial-and-error or on medication affordability rather than the underlying pathophysiology. This is primarily because all guidelines focus on the management of an average patient rather than precision medicine and care.
New types of sodium-glucose co-transporter-2 (SGLT2) inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists extend the capacity to treat type 2 DM with decreased rates of hypoglycemia, less frequent blood glucose self-monitoring, and without weight gain. The early development of these medications was based on metabolic physiology.
The investigation of genetic variation at SLC5A2 (the gene encoding for SGLT2) and GLP1 receptor in individuals and large population studies later supported the mechanisms of action and safety of SGLT2 inhibitors and GLP1 agonists.
Dyslipidemia: In order to pursue PCSK9 as a potential pharmacological target for the treatment of hypercholesterolemia, genetic, phenotypic, and molecular data were involved in the development of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. It has been established that PCSK9 is a hepatic secretory protein that circulates and attaches to LDL receptors, which are the main means by which circulating cholesterol is cleared. This binding then causes LDL receptor endocytosis and subsequent destruction.
By increasing the number of LDL receptors that are available as a result of PCSK9 inhibition, plasma LDL-C levels are decreased. Following administration of alirocumab and evolocumab, a considerable decrease (36–60 percent) in LDL-C was seen, which led to their US FDA approval.
Other than this, precision medicines are also applicable for the preventive measure of adverse drug events, chemotherapy, and cancer, among many others.
Diagnostic, digital devices, imaging advancements, and the availability of plethora of analytics tools operating across numerous institutions and stakeholders are among the key drivers of the market growth. Precision medicine in this entire ecosystem will be functioning using these three key factors:
The report gives an in-depth analysis of the key players involved in the precision medicine market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Technology |
|
Breakup by Application |
|
Breakup by Therapeutic Areas |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market value for precision medicine was USD 81.31 billion in 2023.
The global precision medicine market is anticipated to grow at a CAGR of 12.3% to reach a value of USD 230.96 billion by 2032.
Product type, target disease, end user, and region are the major segments of the market.
The key trends in the precision medicine market are the increasing investments, and continuously running awareness programs by the governments globally.
The precision medicine market has technologies like bioinformatics, gene sequencing, drug discovery, precision molecular diagnostics, and big data analytics.
Precision medicine finds wide applications in diagnostics, therapeutics, healthcare information technology, and alternative medicine.
The areas include oncology, central nervous system, haematology, respiratory, and immunology, among others.
The global precision medicine market is likely to be led by North America.
The end-users include hospitals, diagnostic centres, and research and academic institutes, among others.
The major key players involved in the market are Novartis AG, Pfizer, Inc., Catalent, Inc., Johnson & Johnson, Inc., F. Hoffmann-La Roche A, AstraZeneca plc, Sanofi, Bristol Myers Squibb, Amgen, Inc., Gilead Sciences, Inc., GE Healthcare, Illumina, Inc., Biotechne Corp, Danaher Corporation, and Abbott Laboratories.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share